Stay updated on Switch to Dolutegravir + Rilpivirine Clinical Trial

Sign up to get notified when there's something new on the Switch to Dolutegravir + Rilpivirine Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Switch to Dolutegravir + Rilpivirine Clinical Trial page

  1. Check
    5 days ago
    Change Detected
    Summary
    A service alert has been added regarding planned maintenance starting July 25th, during which most services will be unavailable for over 24 hours.
    Difference
    0.3%
    Check dated 2025-07-11T07:17:10.000Z thumbnail image
  2. Check
    12 days ago
    Change Detected
    Summary
    The page has been updated to version v2.16.5, and the previous version v2.16.4 has been removed. Notably, the information regarding the modernization of ClinicalTrials.gov data ingest scheduled for July 2025 has been deleted.
    Difference
    0.3%
    Check dated 2025-07-04T03:57:35.000Z thumbnail image
  3. Check
    19 days ago
    No Change Detected
  4. Check
    26 days ago
    Change Detected
    Summary
    The expected modernization date for the ClinicalTrials.gov data ingest has been updated from June 2025 to July 2025.
    Difference
    0.3%
    Check dated 2025-06-19T19:36:52.000Z thumbnail image
  5. Check
    33 days ago
    No Change Detected
  6. Check
    40 days ago
    Change Detected
    Summary
    The web page has been updated from version 2.16.1 to version 2.16.2.
    Difference
    0.0%
    Check dated 2025-06-05T11:11:22.000Z thumbnail image
  7. Check
    48 days ago
    Change Detected
    Summary
    The web page has been updated to indicate that the ClinicalTrials.gov data ingest will be modernized in June 2025, allowing API users to provide input before implementation. Additionally, the revision number has been updated from v2.15.2 to v2.16.1.
    Difference
    0.4%
    Check dated 2025-05-29T05:55:51.000Z thumbnail image
  8. Check
    69 days ago
    Change Detected
    Summary
    The page has removed a citation regarding the efficacy, safety, and tolerability of dolutegravir-rilpivirine for HIV-1 maintenance therapy, which is a significant loss of core content.
    Difference
    0.1%
    Check dated 2025-05-07T19:21:37.000Z thumbnail image

Stay in the know with updates to Switch to Dolutegravir + Rilpivirine Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Switch to Dolutegravir + Rilpivirine Clinical Trial page.